|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2001-1-10
|
|
pubmed:abstractText |
Adjuvant therapy has become an integral component of the managment of primary high-risk breast cancer patients. However, a considerable fraction of women receive no benefit from this treatment. This study investigates whether a number of biopathological factors can influence the outcome of patients submitted to adjuvant chemotherapy involving the use of high-dose epirubicin and cyclophosphamide.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0171-5216
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
126
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
722-9
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:11153146-Adult,
pubmed-meshheading:11153146-Aged,
pubmed-meshheading:11153146-Antibiotics, Antineoplastic,
pubmed-meshheading:11153146-Antineoplastic Agents, Alkylating,
pubmed-meshheading:11153146-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11153146-Breast Neoplasms,
pubmed-meshheading:11153146-Chemotherapy, Adjuvant,
pubmed-meshheading:11153146-Cyclophosphamide,
pubmed-meshheading:11153146-Disease-Free Survival,
pubmed-meshheading:11153146-Epirubicin,
pubmed-meshheading:11153146-Female,
pubmed-meshheading:11153146-Humans,
pubmed-meshheading:11153146-Immunohistochemistry,
pubmed-meshheading:11153146-Middle Aged,
pubmed-meshheading:11153146-Multivariate Analysis,
pubmed-meshheading:11153146-Predictive Value of Tests,
pubmed-meshheading:11153146-Prognosis,
pubmed-meshheading:11153146-Proto-Oncogene Proteins c-bcl-2,
pubmed-meshheading:11153146-Receptor, erbB-2,
pubmed-meshheading:11153146-Risk Factors,
pubmed-meshheading:11153146-Survival Analysis,
pubmed-meshheading:11153146-Treatment Outcome,
pubmed-meshheading:11153146-Tumor Suppressor Protein p53
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Role of P53 and BCL-2 in high-risk breast cancer patients treated with adjuvant anthracycline-based chemotherapy.
|
|
pubmed:affiliation |
Pathology Department, Regina Elena Cancer Institute, Rome, Italy.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
